Awad et al. described 38 patients with KRAS G12C mutations, 10 of whom had colorectal cancer, 1 with appendiceal cancer, and the remaining 27 with NSCLC, who all progressed on adagrasib after 12 weeks90. This evidence concerns the gene KRAS and non-small cell lung carcinoma.